o | Preliminary Proxy Statement | ||||
o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | ||||
x | Definitive Proxy Statement | ||||
o | Definitive Additional Materials | ||||
o | Soliciting Material under § 240.14a-12 |
x | No fee required | ||||
o | Fee paid previously with preliminary materials | ||||
o | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
By Order of the Board of Directors | |||||
/s/ Allison Swartz | |||||
Allison Swartz | |||||
Executive Vice President, General Counsel and Secretary | |||||
New York, New York | |||||
April 14, 2023 |
You are cordially invited to attend the virtual Annual Meeting. Whether or not you expect to attend the Annual Meeting, PLEASE VOTE YOUR SHARES. As an alternative to voting online during the Annual Meeting, you may vote your shares by proxy in advance of the Annual Meeting via the internet, by telephone or, if you receive a paper proxy card in the mail, by mailing the completed proxy card. Voting instructions are provided in the Notice of Internet Availability of Proxy Materials, or, if you receive a paper proxy card by mail, the instructions are printed on your proxy card. | ||||||||
Even if you have voted by proxy, you may still vote online during the Annual Meeting. Please note, however, that if your shares are held of record by a broker, bank or other agent and you wish to vote during the Annual Meeting, you must follow the instructions from such organization and will need to obtain a proxy issued in your name from that record holder. | ||||||||
Page | |||||||||||
i | ||
1 | ||
2 | ||
3 | ||
4 | ||
5 | ||
6 | ||
Name | Age | Principal Position with Progyny, Inc. | ||||||||||||||||
Class at | ||||||||||||||||||
Director | ||||||||||||||||||
Kevin Gordon | Director | |||||||||||||||||
Cheryl Scott | Director | |||||||||||||||||
Class II directors continuing in office | ||||||||||||||||||
Peter Anevski | Chief Executive Officer and Director | |||||||||||||||||
Roger Holstein | Director | |||||||||||||||||
Jeff Park | Director | |||||||||||||||||
David Schlanger | Executive Chairman | |||||||||||||||||
Class III directors continuing in office until the 2025 Annual Meeting of Stockholders | ||||||||||||||||||
Fred E. Cohen, M.D., D.Phil. | 66 | Director | ||||||||||||||||
Norman Payson, M.D. | 74 | Director | ||||||||||||||||
Beth Seidenberg, M.D. | 65 | Lead Independent Director |
7 | ||
8 | ||
9 | ||
10 | ||
and Corporate Governance | |||||||||||||||||||||||||||||||||
Lloyd Dean** | X | ||||||||||||||||||||||||||||||||
Fred Cohen, M.D., D.Phil. | |||||||||||||||||||||||||||||||||
Kevin Gordon | X | ||||||||||||||||||||||||||||||||
Roger Holstein | |||||||||||||||||||||||||||||||||
Jeff Park | |||||||||||||||||||||||||||||||||
Norman Payson, M.D. | |||||||||||||||||||||||||||||||||
Cheryl Scott | X | ||||||||||||||||||||||||||||||||
Beth Seidenberg, M.D. |
11 | ||
12 | ||
13 | ||
14 | ||
| | Board Diversity Matrix (As of April 14, 2022) | | | ||||||||||||||||
| | Total Number of Directors | | | | 10 | | | ||||||||||||
| | | | | | Female | | | | Male | | | | Non-Binary | | | | Did Not Disclose Gender | | |
| | Part I: Gender Identity | | | ||||||||||||||||
| | Directors | | | | 3 | | | | 7 | | | | — | | | | 0 | | |
| | Part II: Demographic Background | | | ||||||||||||||||
| | African American or Black | | | | 1 | | | | — | | | | — | | | | — | | |
| | Alaskan Native or Native American | | | | — | | | | — | | | | — | | | | — | | |
| | Asian | | | | — | | | | — | | | | — | | | | — | | |
| | Hispanic or Latinx | | | | — | | | | — | | | | — | | | | — | | |
| | Native Hawaiian or Pacific Islander | | | | — | | | | — | | | | — | | | | — | | |
| | White | | | | 2 | | | | 7 | | | | — | | | | — | | |
| | Two or More Races or Ethnicities | | | | — | | | | — | | | | — | | | | — | | |
| | LGBTQ+ | | | | 1 | | | ||||||||||||
| | Did Not Disclose Demographic Background | | | | 0 | | |
Board Diversity Matrix (As of April 14, 2023) | ||||||||||||||
Total Number of Directors | 10 | |||||||||||||
Female | Male | Non-Binary | Did Not Disclose Gender | |||||||||||
Part I: Gender Identity | ||||||||||||||
Directors | 2 | 8 | — | — | ||||||||||
Part II: Demographic Background | ||||||||||||||
African American or Black | — | 1 | — | — | ||||||||||
Alaskan Native or Native American | — | — | — | — | ||||||||||
Asian | — | — | — | — | ||||||||||
Hispanic or Latinx | — | — | — | — | ||||||||||
Native Hawaiian or Pacific Islander | — | — | — | — | ||||||||||
White | 2 | 6 | — | — | ||||||||||
Two or More Races or Ethnicities | — | — | — | — | ||||||||||
LGBTQ+ | 1 | |||||||||||||
Did Not Disclose Demographic Background | 1 |
15 | ||
16 | ||
| | | Fiscal Year Ended | | |||
| | | 2021 | | | 2020 | |
| | | (in thousands) | | |||
Audit Fees(1) | | | $700 | | | $775 | |
Audit-related Fees(2) | | | — | | | — | |
Tax Fees(3) | | | 119 | | | 112 | |
All Other Fees(4) | | | — | | | 4 | |
Total Fees | | | $819 | | | $891 | |
Fiscal Year Ended | |||||||||||
2022 | 2021 | ||||||||||
(in thousands) | |||||||||||
Audit Fees(1) | $ | 775 | $ | 700 | |||||||
Audit-related Fees(2) | — | — | |||||||||
Tax Fees(3) | 172 | 119 | |||||||||
All Other Fees(4) | — | — | |||||||||
Total Fees | $ | 947 | $ | 819 |
17 | ||
18 | ||
Name | Age | Principal Position | ||||||||||||||||||
David Schlanger | Executive Chairman | |||||||||||||||||||
Peter Anevski | Chief Executive Officer and Director | |||||||||||||||||||
Executive Vice President, General Counsel and Secretary | ||||||||||||||||||||
Mark Livingston | Chief Financial Officer | |||||||||||||||||||
Michael Sturmer | President |
19 | ||
20 | ||
What We Do | What We Don’t Do | |||||||||||||||
Deliver a significant portion of executive compensation through long-term equity to align interests with stockholders | No pledging or hedging of Progyny stock | |||||||||||||||
Engage an independent compensation consultant | No excessive perquisites | |||||||||||||||
Benchmark certain pay against industry peers to offer market-competitive compensation | No supplemental executive retirement plans | |||||||||||||||
Set challenging company metrics and targets | No compensation-related tax gross-ups | |||||||||||||||
Conduct an annual executive compensation review | No incentives that encourage excessive |
National Research Corp | |||||||||
Corvel Corp | |||||||||
Masimo Corporation | |||||||||
MultiPlan Corporation |
21 | ||
Named Executive Officer | | | Fiscal 2021 Base Salary | | |||
David Schlanger | | | | $ | 500,000 | | |
Peter Anevski | | | | $ | 425,000 | | |
Mark Livingston | | | | $ | 425,000 | | |
Jennifer Bealer | | | | $ | 300,000 | | |
Lisa Greenbaum | | | | $ | 113,751(1) | | |
Named Executive Officer | Fiscal 2022 Annual Base Salary | |||||||
Peter Anevski | $500,000 | |||||||
Mark Livingston | $425,000 | |||||||
David Schlanger | $250,000 | |||||||
Allison Swartz | $350,000(1) | |||||||
Michael Sturmer | $425,000 |
22 | ||
Named Executive Officer | Target Percentage Salary | |||||||||||
Michael Sturmer |
Performance Metric/Goal | Actual | Assessment | ||||||||||||||||
Sales and Account Management – grow client base, upsells to existing clients and client retention | Exceeds expectations | |||||||||||||||||
Clinical Outcomes and Scientific Leadership – generate industry leading clinical outcomes that exceed national averages | All clinical outcomes substantially exceeded most recently reported national averages and are industry leading | Exceeds expectations | ||||||||||||||||
Member Services – continue to improve and refine the member experience to maintain competitive differentiation | NPS score of | Exceeds expectations |
Performance Metric/Goal | Actual | Assessment | |||||||||||||||
Provider Network and Relations – continue to have a high quality network and maintain unique collaborative relationship with network providers | Continued to grow network and | Meets expectations |
Organization – maintain the unique mission-driven and collaborative culture | Positive results from employee engagement survey and | Exceeds expectations | ||||||||||||||||
Strategic – | Exceeds expectations |
Name | | Target | | Overall Assessment | | Actual Bonus Payout | | Name | Target | Overall Assessment | Actual Bonus Payout | |||||||||||||||||||||||||
David Schlanger | | | $ | 375,000 | | | Meets expectations | | | $ | 350,000 | | | |||||||||||||||||||||||
Peter Anevski | | | $ | 318,750 | | | Exceeds expectations | | | $ | 350,000 | | | Peter Anevski | $500,000 | Exceeds expectations | $500,000 | |||||||||||||||||||
Mark Livingston | | | $ | 255,000 | | | Meets expectations | | | $ | 255,000 | | | Mark Livingston | $255,000 | Exceeds expectations | $255,000 | |||||||||||||||||||
Jennifer Bealer | | | $ | 120,000 | | | Exceeds expectations | | | $ | 150,000 | | | |||||||||||||||||||||||
Lisa Greenbaum | | N/A | | N/A | | N/A | | |||||||||||||||||||||||||||||
David Schlanger | David Schlanger | $250,000 | Exceeds expectations | $250,000 | ||||||||||||||||||||||||||||||||
Allison Swartz | Allison Swartz | N/A | N/A | N/A | ||||||||||||||||||||||||||||||||
Michael Sturmer | Michael Sturmer | $318,750 | Exceeds expectations | $325,000 |
Named Executive Officer | | | 2021 Stock Options Granted | | | 2021 RSUs Granted | | ||||||
Mark Livingston | | | | | 270,000 | | | | | | 82,000 | | |
Jennifer Bealer | | | | | 135,000 | | | | | | 37,000 | | |
Lisa Greenbaum | | | | | 20,000 | | | | | | 7,000 | | |
Named Executive Officer | 2022 Stock Options Granted | 2022 RSUs Granted | 2022 PSUs Granted | |||||||||||||||||
Peter Anevski | 1,800,000 | 250,000 | 250,000 | |||||||||||||||||
Mark Livingston | 250,000 | — | — | |||||||||||||||||
David Schlanger | 333,000 | 84,000 | 83,000 | |||||||||||||||||
Allison Swartz | 175,000 | 60,000 | — | |||||||||||||||||
Michael Sturmer | 320,000 | 7,000 | — |
24 | ||
25 | ||
26 | ||
Name and Principal Position during 2021 | | | Year | | | Salary ($) | | | Bonus ($)(1) | | | Stock Awards ($)(2) | | | Option Awards ($)(2) | | | Non-Equity Incentive Plan Compensation ($)(3) | | | All Other Compensation ($)(4) | | | Total ($) | | ||||||||||||||||||||||||
David Schlanger Chief Executive Officer | | | | | 2021 | | | | | | 500,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | 350,000 | | | | | | 12,462 | | | | | | 862,462 | | |
| | | | | 2020 | | | | | | 500,000 | | | | | | 125,000 | | | | | | — | | | | | | — | | | | | | 350,000 | | | | | | 12,312 | | | | | | 987,312 | | |
| | | | | 2019 | | | | | | 431,250 | | | | | | — | | | | | | — | | | | | | 4,240,075 | | | | | | 250,000 | | | | | | 42,871 | | | | | | 4,964,196 | | |
Peter Anevski President and Chief Operating Officer | | | | | 2021 | | | | | | 425,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | 350,000 | | | | | | 10,770 | | | | | | 785,770 | | |
| | | | | 2020 | | | | | | 425,000 | | | | | | 156,250 | | | | | | — | | | | | | — | | | | | | 318,750 | | | | | | 9,861 | | | | | | 909,861 | | |
| | | | | 2019 | | | | | | 375,000 | | | | | | — | | | | | | — | | | | | | 3,865,951 | | | | | | 250,000 | | | | | | 30,714 | | | | | | 4,251,665 | | |
Mark Livingston Chief Financial Officer | | | | | 2021 | | | | | | 425,000 | | | | | | — | | | | | | 4,521,210 | | | | | | 7,586,995 | | | | | | 255,000 | | | | | | 275,467 | | | | | | 13,063,672 | | |
| | | | | 2020 | | | | | | 389,776 | | | | | | 127,812 | | | | | | 299,760 | | | | | | 94,529 | | | | | | 207,188 | | | | | | 132,230 | | | | | | 1,251,295 | | |
Jennifer Bealer Executive Vice President and General Counsel | | | | | 2021 | | | | | | 300,000 | | | | | | — | | | | | | 2,299,260 | | | | | | 4,309,487 | | | | | | 150,000 | | | | | | 10,170 | | | | | | 7,068,917 | | |
| | | | | 2020 | | | | | | 300,000 | | | | | | 70,000 | | | | | | 299,760 | | | | | | 94,529 | | | | | | 120,000 | | | | | | 9,120 | | | | | | 893,409 | | |
Lisa Greenbaum(5) Executive Vice President and Chief Client Officer | | | | | 2021 | | | | | | 113,751 | | | | | | — | | | | | | 299,460 | | | | | | 438,920 | | | | | | — | | | | | | 26,054 | | | | | | 878,185 | | |
| | | | | 2020 | | | | | | 325,000 | | | | | | 75,000 | | | | | | 81,060 | | | | | | 94,529 | | | | | | 225,000 | | | | | | 56,574 | | | | | | 857,163 | | |
Name and Principal Position during 2022 | Year | Salary ($) | Bonus ($)(1) | Stock Awards ($)(2) | Option Awards ($)(2) | Non-Equity Incentive Plan Compensation ($)(3) | All Other Compensation ($)(4) | Total ($) | ||||||||||||||||||||||||||||||||||||||||||
Peter Anevski Chief Executive Officer | 2022 | 500,000 | — | 25,175,000 | 42,393,600 | 500,000 | 11,472 | 68,580,072 | ||||||||||||||||||||||||||||||||||||||||||
2021 | 425,000 | — | — | — | 350,000 | 10,770 | 785,770 | |||||||||||||||||||||||||||||||||||||||||||
2020 | 425,000 | 156,250 | — | — | 318,750 | 9,861 | 909,861 | |||||||||||||||||||||||||||||||||||||||||||
Mark Livingston Chief Financial Officer | 2022 | 425,000 | — | — | 5,339,500 | 255,000 | 13,872 | 6,033,372 | ||||||||||||||||||||||||||||||||||||||||||
2021 | 425,000 | — | 4,521,210 | 7,586,995 | 255,000 | 275,467 | 13,063,672 | |||||||||||||||||||||||||||||||||||||||||||
2020 | 389,776 | 127,812 | 299,760 | 94,529 | 207,188 | 132,230 | 1,251,295 | |||||||||||||||||||||||||||||||||||||||||||
David Schlanger Executive Chairman | 2022 | 250,000 | — | 8,408,450 | 8,427,298 | 250,000 | 10,408 | 17,346,156 | ||||||||||||||||||||||||||||||||||||||||||
2021 | 500,000 | — | — | — | 350,000 | 12,462 | 862,462 | |||||||||||||||||||||||||||||||||||||||||||
2020 | 500,000 | 125,000 | — | — | 350,000 | 12,312 | 987,312 | |||||||||||||||||||||||||||||||||||||||||||
Allison Swartz(5) Executive Vice President and General Counsel | 2022 | 33,205 | 140,000 | 2,215,200 | 3,503,675 | — | 149 | 5,892,229 | ||||||||||||||||||||||||||||||||||||||||||
Michael Sturmer President | 2022 | 425,000 | — | 311,710 | 6,862,078 | 325,000 | 11,498 | 7,935,286 |
27 | ||
Name | | | Grant Date | | | Threshold ($) | | | Target ($) | | | Maximum ($) | | | All Other Stock Awards: Number of Shares of Stock or Units (#) | | | All Other Option Awards: Number of Securities Underlying Options (#) | | | Exercise or Base Price of Option Awards ($/Sh) | | | Grant Date Fair Value of Stock and Option Awards($)(1) | | ||||||||||||||||||||||||
David Schlanger | | | | | N/A | | | | | | — | | | | | | 375,000(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Peter Anevski | | | | | N/A | | | | | | — | | | | | | 318,750(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Mark Livingston | | | | | N/A | | | | | | — | | | | | | 255,000(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,000 | | | | | | — | | | | | | — | | | | | | 299,460 | | | ||
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,000 | | | | | | 42.78 | | | | | | 438,920 | | | ||
| | | 09/01/21(4) | | | | | | — | | | | | | — | | | | | | — | | | | | | 75,000 | | | | | | — | | | | | | — | | | | | | 4,221,750 | | | ||
| | | 09/01/21(4) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 250,000 | | | | | | 56.29 | | | | | | 7,148,075 | | | ||
Jennifer Bealer | | | | | N/A | | | | | | — | | | | | | 120,000(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,000 | | | | | | — | | | | | | — | | | | | | 299,460 | | | ||
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 9,000 | | | | | | 42.78 | | | | | | 438,920 | | | ||
| | | 11/08/21(5) | | | | | | — | | | | | | — | | | | | | — | | | | | | 30,000 | | | | | | — | | | | | | — | | | | | | 1,999,800 | | | ||
| | | 11/08/21(5) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 115,000 | | | | | | 66.66 | | | | | | 3,870,567 | | | ||
Lisa Greenbaum | | | | | N/A | | | | | | — | | | | | | 325,000(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,000 | | | | | | — | | | | | | — | | | | | | 299,460 | | | ||
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,000 | | | | | | 42.78 | | | | | | 438,920 | | |
Estimated Future Payouts Under Non-Equity Incentive Plan Awards(2) | Estimated Future Payouts Under Equity Incentive Plan Awards | All Other Stock Awards: Number of Shares of Stock or Units (#) | All Other Option Awards: Number of Securities Underlying Options (#) | Exercise or Base Price of Option Awards ($/Sh) | Grant Date Fair Value of Stock and Option Awards($)(1) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | Grant Date | Threshold ($) | Target ($) | Maximum ($) | Threshold (#) | Target (#) | Maximum (#) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Peter Anevski | N/A | — | 500,000 | 1,000,000 | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1/1/22 (3) | — | — | — | — | — | — | 250,000 | — | 12,587,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1/1/22 (3) | — | — | — | — | 250,000 | 250,000 | — | — | 12,587,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1/1/22 (3) | — | — | — | — | — | — | 1,000,000 | 50.35 | 25,307,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
10/18/22 (4) | — | — | — | — | — | — | — | 800,000 | 39.39 | 17,086,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mark Livingston | N/A | — | 255,000 | 510,000 | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
10/18/22 (4) | — | — | — | — | — | — | — | 250,000 | 39.39 | 5,339,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
David Schlanger | N/A | — | 250,000 | 500,000 | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1/1/22 (3) | — | — | — | — | — | — | 84,000 | — | 4,229,400 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1/1/22 (3) | — | — | — | — | 83,000 | 83,000 | — | — | — | 4,179,050 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1/1/22 (3) | — | — | — | — | — | — | 333,000 | 50.35 | 8,427,298 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Allison Swartz | N/A | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
11/28/22 (5) | — | — | — | — | — | — | 60,000 | — | — | 2,215,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
11/28/22 (5) | — | — | — | — | — | — | — | 175,000 | 36.92 | 3,503,675 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Michael Sturmer | N/A | — | 318,750 | 637,500 | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3/2/22 (6) | — | — | — | — | — | — | 7,000 | — | — | 311,710 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3/2/22 (6) | — | — | — | — | — | — | — | 20,000 | 44.53 | 571,846 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
10/18/22 (4) | — | — | — | — | — | — | — | 300,000 | 39.39 | 6,407,400 |
28 | ||
29 | ||
30 | ||
Option Awards | Stock Awards | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | Grant Date | Number of Securities Underlying Unexercised Options (#) Exercisable | Number of Securities Underlying Unexercised Options (#) Unexercisable | Option Exercise Price ($) | Option Expiration Date | Number of Shares or Units of Stock That Have Not Vested (#) | Market Value of Shares or Units of Stock That Have Not Vested ($)(1) | Equity Incentive Plan Awards: Number of unearned Shares, Units or Other Rights That Have Not Vested (#) | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(1) | |||||||||||||||||||||||||||||||||||||||||||||||
Peter Anevski | 10/18/2022 | — | 800,000(2) | 39.3900 | 10/17/2032 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
1/1/2022 | — | 1,000,000(3) | 50.3500 | 12/31/2031 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
1/1/2022 | — | — | — | — | 250,000(3) | 7,787,500 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
1/1/2022 | — | — | — | — | — | — | 250,000(4) | 7,787,500 | ||||||||||||||||||||||||||||||||||||||||||||||||
5/24/2019 | 1,177,949(5) | 177,607(5) | 3.9545 | 05/23/2029 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
8/17/2018 | 34,042(6) | — | 1.5000 | 08/16/2028 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
8/4/2017 | 472,107(6) | — | 0.9091 | 8/3/2027 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Mark Livingston | 10/18/2022 | — | 250,000(2) | 39.3900 | 10/17/2032 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
9/1/2021 | 78,125(7) | 171,875(7) | 56.2900 | 8/31/2031 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
9/1/2021 | — | — | — | — | 51,561(7) | 1,606,125 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
3/3/2021 | 8,750(8) | 11,250(8) | 42.7800 | 3/2/2031 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
3/3/2021 | — | — | — | — | 3,935(8) | 122,575 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
5/4/2020 | — | — | — | — | 2,500(9) | 77,875 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
3/9/2020 | 3,376(10) | 2,810(10) | 23.1600 | 3/8/2030 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
3/9/2020 | — | — | — | — | 1,091(10) | 33,895 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
6/4/2019 | 96,251(11) | 34,376(11) | 3.9545 | 6/3/2029 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
David Schlanger | 1/1/2022 | — | 333,000(3) | 50.3500 | 12/31/2031 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
1/1/2022 | — | — | — | — | 84,000(3) | 2,616,600 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
1/1/2022 | — | — | — | — | — | — | 83,000(4) | 2,585,450 | ||||||||||||||||||||||||||||||||||||||||||||||||
5/24/2019 | 1,675,229(5) | 194,793(5) | 3.9545 | 05/23/2029 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
8/17/2018 | 202,794(6) | — | 1.5000 | 8/16/2028 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
8/4/2017 | 1,232,229(6) | — | 0.9091 | 8/03/2027 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Allison Swartz | 11/28/2022 | — | 175,000(12) | 36.9200 | 11/27/2032 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
11/28/2022 | — | — | — | — | 60,000(12) | 1,869,000 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Michael Sturmer | 10/18/2022 | — | 300,000(2) | 39.3900 | 10/17/2032 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
3/2/2022 | — | 20,000(13) | 44.5300 | 3/1/2032 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
3/2/2022 | — | — | — | — | 7,000(13) | 218,050 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
3/3/2021 | 262,500(8) | 337,500(8) | 42.7800 | 3/2/2031 | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||
3/3/2021 | — | — | — | — | — | — | — | 140,625(8) | 4,380,469 | — | — | — |
31 | ||
Option Awards | Stock Awards | |||||||||||||||||||||||||
Name | Number of Shares Acquired on Exercise (#)(1) | Value Realized on Exercise ($)(4) | Number of Shares Acquired on Vesting (#)(1) | Value Realized on Vesting ($)(5) | ||||||||||||||||||||||
Peter Anevski | 320,080 | 11,966,776 | — | — | ||||||||||||||||||||||
Mark Livingston | — | — | 29,880(2) | 1,163,371 | ||||||||||||||||||||||
David Schlanger | 1,002,156 | 42,217,365 | — | — | ||||||||||||||||||||||
Allison Swartz | — | — | — | — | ||||||||||||||||||||||
Michael Sturmer | — | — | 109,375(3) | 4,014,531 |
32 | ||
David Schlanger | |||||||||||||||||||||||||||||||||||||||||||
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||
Name | | | Number of Shares Acquired on Exercise (#)(1) | | | Value Realized on Exercise ($)(7) | | | Number of Shares Acquired on Vesting (#)(1) | | | Value Realized on Vesting ($)(8) | | ||||||||||||
David Schlanger | | | | | 1,500,000 | | | | | | 79,489,166 | | | | | | — | | | | | | — | | |
Peter Anevski | | | | | 403,538 | | | | | | 23,140,575 | | | | | | — | | | | | | — | | |
Mark Livingston | | | | | 78,439(2) | | | | | | 4,689,959 | | | | | | 4,033(3) | | | | | | 212,696 | | |
Jennifer Bealer | | | | | 71,579(4) | | | | | | 3,658,585 | | | | | | 4,033 | | | | | | 212,696 | | |
Lisa Greenbaum | | | | | 57,668(5) | | | | | | 2,829,553 | | | | | | 876(6) | | | | | | 36,941 | | |
33 | ||
34 | ||
Name | | | Benefit | | | Termination Without Cause or for Good Reason / Cause (no Change in Control) ($) | | | Termination Without Cause or for Good Reason / Cause in Connection with a Change in Control ($)(7) | | ||||||
David Schlanger | | | Cash | | | | | 850,000(1) | | | | | | 850,000(1) | | |
| | | Equity Acceleration | | | | | 21,690,175(3) | | | | | | 30,727,693(4) | | |
| | | All Other Payments or Benefits | | | | | 28,723(5) | | | | | | 28,723(5) | | |
| | | Gross Up Payment | | | | | — | | | | | | — | | |
| | | Total | | | | | 22,568,898 | | | | | | 31,606,416 | | |
Peter Anevski | | | Cash | | | | | 775,000(1) | | | | | | 775,000(1) | | |
| | | Equity Acceleration | | | | | 19,776,314(3) | | | | | | 28,016,479(4) | | |
| | | All Other Payments or Benefits | | | | | 42,107(5) | | | | | | 42,107(5) | | |
| | | Gross Up Payment | | | | | — | | | | | | — | | |
| | | Total | | | | | 20,593,421 | | | | | | 28,833,586 | | |
Mark Livingston | | | Cash | | | | | 467,500(2) | | | | | | 467,500(2) | | |
| | | Equity Acceleration | | | | | 2,186,996(3) | | | | | | 10,191,037(4) | | |
| | | All Other Payments or Benefits | | | | | 31,228(5) | | | | | | 31,228(5) | | |
| | | Total | | | | | 2,685,724 | | | | | | 10,689,765 | | |
Jennifer Bealer(6) | | | Cash | | | | | — | | | | | | — | | |
| | | Equity Acceleration | | | | | — | | | | | | — | | |
| | | All Other Payments or Benefits | | | | | — | | | | | | — | | |
| | | Total | | | | | — | | | | | | — | | |
Name | Benefit | Termination Without Cause or for Good Reason / Cause (no Change in Control) ($) | Termination Without Cause or for Good Reason / Cause in Connection with a Change in Control ($)(6) | Death | ||||||||||||||||||||||
Peter Anevski | Cash | 1,000,000(1) | 1,000,000(1) | — | ||||||||||||||||||||||
Equity Acceleration | 16,024,642(2) | 20,405,111(3) | 12,617,611(3) | |||||||||||||||||||||||
All Other Payments or Benefits | 31,719(4) | 31,719(4) | — | |||||||||||||||||||||||
Gross Up Payment | — | — | — | |||||||||||||||||||||||
Total | 17,056,361 | 21,436,830 | 12,617,611 | |||||||||||||||||||||||
Mark Livingston | Cash | 467,500(1) | 467,500(1) | — | ||||||||||||||||||||||
Equity Acceleration | 1,315,753(2) | 2,797,884(3) | 2,797,884(3) | |||||||||||||||||||||||
All Other Payments or Benefits | 12,172(4) | 12,172(4) | — | |||||||||||||||||||||||
Total | 1,795,425 | 3,277,556 | 2,797,884 | |||||||||||||||||||||||
David Schlanger | Cash | 500,000(1) | 500,000(1) | — | ||||||||||||||||||||||
Equity Acceleration | 9,027,706(2) | 10,499,543(3) | 7,914,093(3) | |||||||||||||||||||||||
All Other Payments or Benefits | 22,438(4) | 22,438(4) | — | |||||||||||||||||||||||
Gross Up Payment | — | — | — | |||||||||||||||||||||||
Total | 9,550,144 | 11,021,981 | 7,914,093 | |||||||||||||||||||||||
Allison Swartz(5) | Cash | — | — | — | ||||||||||||||||||||||
Equity Acceleration | — | — | 1,869,000(3) | |||||||||||||||||||||||
All Other Payments or Benefits | — | — | — | |||||||||||||||||||||||
Gross Up Payment | — | — | — | |||||||||||||||||||||||
Total | — | — | 1,869,000 | |||||||||||||||||||||||
Michael Sturmer | Cash | 743,750(1) | 743,750(1) | — | ||||||||||||||||||||||
Equity Acceleration | 2,042,350(2) | 4,598,519(3) | 4,598,519(3) | |||||||||||||||||||||||
All Other Payments or Benefits | 7,828(4) | 7,828(4) | — | |||||||||||||||||||||||
Gross Up Payment | — | — | — | |||||||||||||||||||||||
Total | 2,793,928 | 5,350,097 | 4,598,519 |
Plan Category | | | Number of Shares to be issued upon exercise of outstanding options, warrants and rights (#) | | | Weighted-average exercise price of outstanding options, warrants and rights ($) | | | Number of Shares remaining available for future issuance under equity compensation plans (excluding shares reflected in the first column) (#) | | |||||||||
Equity compensation plans approved by security holders | | | | | 17,254,882(1) | | | | | $ | 24.25 | | | | | | 5,721,311(2) | | |
Equity compensation plan not approved by security holders | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | | 17,254,882 | | | | | $ | 24.25 | | | | | | 5,721,311 | | |
35 | ||
Position | | | Annual Retainer | | |||
Board of Directors | | | | $ | 40,000 | | |
Board of Directors Independent Chair or Lead Independent Director | | | | $ | 25,000 | | |
Audit Committee Chair | | | | $ | 20,000 | | |
Compensation Committee Chair | | | | $ | 10,000 | | |
Nominating and Corporate Governance Committee Chair | | | | $ | 7,500 | | |
Position | | | Annual Committee Grant (Options) | | | Annual Committee Grant (RSUs) | | ||||||
Board of Directors | | | | $ | 338,587 | | | | | $ | 139,750 | | |
Board of Directors Independent Chair or Lead Independent Director | | | | $ | 54,174 | | | | | $ | 55,900 | | |
Audit Committee Chair | | | | $ | 40,631 | | | | | $ | 27,950 | | |
Compensation Committee Chair | | | | $ | 27,101 | | | | | $ | 27,950 | | |
Nominating and Corporate Governance Committee Chair | | | | $ | 13,544 | | | | | $ | 27,950 | | |
Name(5) | | | Fees Earned or Paid in Cash ($) | | | Stock Awards ($)(1) | | | Option Awards ($)(1) | | | Total ($) | | ||||||||||||
Beth Seidenberg, M.D. | | | | $ | 66,172(2) | | | | | $ | 195,572 | | | | | $ | 430,925 | | | | | $ | 692,669 | | |
Malissia Clinton | | | | $ | 37,452 | | | | | $ | 139,694 | | | | | $ | 371,493 | | | | | $ | 548,640 | | |
Fred Cohen, M.D., D.Phil. | | | | $ | 50,000(3) | | | | | $ | 167,633 | | | | | $ | 401,222 | | | | | $ | 618,855 | | |
Kevin Gordon | | | | $ | 40,000 | | | | | $ | 139,694 | | | | | $ | 371,493 | | | | | $ | 551,187 | | |
Roger Holstein | | | | $ | 37,452 | | | | | $ | 139,694 | | | | | $ | 371,493 | | | | | $ | 548,640 | | |
Jeff Park | | | | $ | 61,079(4) | | | | | $ | 167,633 | | | | | $ | 416,074 | | | | | $ | 644,786 | | |
Norman Payson, M.D. | | | | $ | 47,500 | | | | | $ | 167,633 | | | | | $ | 386,345 | | | | | $ | 601,478 | | |
Cheryl Scott | | | | $ | 40,000 | | | | | $ | 139,694 | | | | | $ | 371,493 | | | | | $ | 551,187 | | |
Name | | | Options Outstanding at Fiscal Year End (Exercisable) | | | Options Outstanding at Fiscal Year End (Unexercisable) | | | Restricted Stock Units Outstanding at Fiscal Year End(1) | | |||||||||
Beth Seidenberg, M.D. | | | | | 66,800 | | | | | | 39,615 | | | | | | 3,094 | | |
Malissia Clinton | | | | | 11,000 | | | | | | 47,658 | | | | | | 2,210 | | |
Fred Cohen, M.D., D. Phil. | | | | | 59,096 | | | | | | 33,981 | | | | | | 2,652 | | |
Kevin Gordon | | | | | 48,833 | | | | | | 34,825 | | | | | | 2,210 | | |
Roger Holstein | | | | | 11,000 | | | | | | 47,658 | | | | | | 2,210 | | |
Jeff Park | | | | | 62,863 | | | | | | 39,180 | | | | | | 2,652 | | |
Norman Payson | | | | | 95,225 | | | | | | 35,043 | | | | | | 2,652 | | |
Cheryl Scott | | | | | 48,834 | | | | | | 34,824 | | | | | | 2,210 | | |
Value of Initial Fixed $100 Investment Based On(7): | ||||||||||||||||||||||||||||||||||||||||||||||||||
Year | Summary Compensation Table Total for PEO(1) | Compensation Actually Paid to PEO($)(2)(3) | Average Summary Compensation Table Total for non-PEO NEOs($)(4) | Average Compensation Actually Paid to non-PEO NEOs ($)(2)(4)(5) | Total Shareholder Return ($) | Peer Group Total Shareholder Return ($)(6) | Net Income (thousands) ($) | Revenue (thousands) ($)(8) | ||||||||||||||||||||||||||||||||||||||||||
2022 | 68,580,072 | 31,304,264 | 9,301,761 | (708,249) | 113.48 | 133.44 | 30,358 | 786,913 | ||||||||||||||||||||||||||||||||||||||||||
2021 | 862,462 | 12,703,237 | 5,449,136 | 6,880,527 | 183.42 | 138.35 | 65,769 | 500,621 | ||||||||||||||||||||||||||||||||||||||||||
2020 | 987,312 | 19,593,349 | 793,843 | 2,978,511 | 154.43 | 111.43 | 46,459 | 344,858 |
36 | ||
2022 ($) | 2021 ($) | 2020 ($) | ||||||||||||||||||
Summary Compensation Table Total | 68,580,072 | 862,462 | 987,312 | |||||||||||||||||
Less, value of Stock Awards and Options Awards in Summary Compensation Table | (67,568,600) | — | — | |||||||||||||||||
Plus, year-end fair value of outstanding and unvested equity awards granted in the year | 39,410,940 | — | — | |||||||||||||||||
Plus/Less, year-over-year change in fair value of outstanding and unvested equity awards granted in prior years | (3,368,117) | 5,284,970 | 18,392,284 | |||||||||||||||||
Plus/Less, year-over-year change in fair value of equity awards granted in prior years that vested in the year | (5,750,031) | 6,555,805 | 213,753 | |||||||||||||||||
Compensation Actually Paid to PEOs | 31,304,264 | 12,703,237 | 19,593,349 |
2022 ($) | 2021 ($) | 2020 ($) | ||||||||||||||||||
Average Summary Compensation Table Total | 9,301,761 | 5,449,136 | 793,843 | |||||||||||||||||
Less, average value of Stock Awards and Options Awards in Summary Compensation Table | (8,766,978) | (4,777,735) | (188,928) | |||||||||||||||||
Plus, average year-end fair value of outstanding and unvested equity awards granted in the year | 5,604,053 | 3,820,260 | 360,083 | |||||||||||||||||
Plus/Less, average year-over-year change in fair value of outstanding and unvested equity awards granted in prior years | (3,796,209) | 1,617,046 | 4,340,920 | |||||||||||||||||
Plus, average fair value of equity awards granted and vested in the year | — | — | 27,950 | |||||||||||||||||
Plus/Less, average year-over-year change in fair value of equity awards granted in prior years that vested in the year | (3,050,876) | 1,950,757 | (75,463) | |||||||||||||||||
Less, average fair value of equity awards granted in prior years that failed to meet vesting conditions in the year | — | (1,178,937) | (2,279,894) | |||||||||||||||||
Average Compensation Actually Paid to non-PEO NEOs | (708,249) | 6,880,527 | 2,978,511 |
37 | ||
38 | ||
39 | ||
Plan Category | Number of Shares to be issued upon exercise of outstanding options, warrants and rights (#) | Weighted-average exercise price of outstanding options, warrants and rights ($) | Number of Shares remaining available for future issuance under equity compensation plans (excluding shares reflected in the first column) (#) | |||||||||||||||||
Equity compensation plans approved by security holders | 21,789,539(1) | $ | 31.24 | 4,547,752(2) | ||||||||||||||||
Equity compensation plan not approved by security holders | — | — | — | |||||||||||||||||
Total | 21,789,539 | $ | 31.24 | 4,547,752 |
40 | ||
Position | Annual Retainer ($) | |||||||
Board of Directors | 40,000 | |||||||
Board of Directors Independent Chair or Lead Independent Director | 25,000 | |||||||
Audit Committee Chair | 20,000 | |||||||
Compensation Committee Chair | 10,000 | |||||||
Nominating and Corporate Governance Committee Chair | 7,500 |
Position | Initial Grant (#) | |||||||
Board of Directors | 44,000 | |||||||
Board of Directors Independent Chair or Lead Independent Director | 8,800 | |||||||
Audit Committee Chair | 6,600 | |||||||
Compensation Committee Chair | 4,400 | |||||||
Nominating and Corporate Governance Committee Chair | 2,200 |
Position | Annual Committee Grant (Options) ($) | Annual Committee Grant (RSUs) ($) | ||||||||||||
Board of Directors | 338,587 | 139,750 | ||||||||||||
Board of Directors Independent Chair or Lead Independent Director | 54,174 | 55,900 | ||||||||||||
Audit Committee Chair | 40,631 | 27,950 | ||||||||||||
Compensation Committee Chair | 27,101 | 27,950 | ||||||||||||
Nominating and Corporate Governance Committee Chair | 13,544 | 27,950 |
Position | RSUs (#) | Options (#) | ||||||||||||
Board of Directors | 2,900 | 14,500 | ||||||||||||
Lead Independent Director | 1,160 | 2,320 | ||||||||||||
Audit Committee Chair | 580 | 1,740 | ||||||||||||
Compensation Committee Chair | 580 | 1,160 | ||||||||||||
Nominating and Corporate Governance Committee Chair | 580 | 580 |
41 | ||
Name(8) | Fees Earned or Paid in Cash ($) | Stock Awards ($)(1) | Option Awards ($)(1) | Total ($) | ||||||||||||||||||||||
Beth Seidenberg, M.D. | 70,120(2) | 155,173 | 334,536 | 559,830 | ||||||||||||||||||||||
Malissia Clinton(3) | 11,806 | — | — | 11,806 | ||||||||||||||||||||||
Fred Cohen, M.D., D.Phil. | 50,000(4) | 133,006 | 311,465 | 494,470 | ||||||||||||||||||||||
Lloyd Dean(5) | 13,374(6) | — | 937,322(5) | 950,696 | ||||||||||||||||||||||
Kevin Gordon | 40,000 | 110,838 | 288,393 | 439,231 | ||||||||||||||||||||||
Roger Holstein | 40,000 | 110,838 | 288,393 | 439,231 | ||||||||||||||||||||||
Jeff Park | 64,714(7) | 133,006 | 323,000 | 520,720 | ||||||||||||||||||||||
Norman Payson, M.D. | 47,500 | 133,006 | 299,929 | 480,434 | ||||||||||||||||||||||
Cheryl Scott | 40,000 | 110,838 | 288,393 | 439,231 |
42 | ||
Name | Options Outstanding at Fiscal Year End (Exercisable) | Options Outstanding at Fiscal Year End (Unexercisable) | Restricted Stock Units Outstanding at Fiscal Year End(1) | |||||||||||||||||
Beth Seidenberg, M.D. | 99,816 | 25,317 | 4,060 | |||||||||||||||||
Lloyd Dean | — | 44,584 | — | |||||||||||||||||
Fred Cohen, M.D., D. Phil. | 87,027 | 23,170 | 3,480 | |||||||||||||||||
Kevin Gordon | 74,491 | 23,667 | 2,900 | |||||||||||||||||
Roger Holstein | 36,658 | 36,500 | 2,900 | |||||||||||||||||
Jeff Park | 92,876 | 27,159 | 3,480 | |||||||||||||||||
Norman Payson | 123,669 | 21,679 | 3,480 | |||||||||||||||||
Cheryl Scott | 74,492 | 23,666 | 2,900 |
43 | ||
| | | Beneficial Ownership(1) | | |||||||||
Beneficial Owner | | | Number of Shares | | | Percent of Total | | ||||||
Greater than 5% Stockholders | | | | | | | | | | | | | |
TPG Biotechnology Partners III, L.P.(2) | | | | | 10,565,351 | | | | | | 11.4% | | |
BlackRock(3) | | | | | 7,923,625 | | | | | | 8.6% | | |
Macquarie Group Limited(4) | | | | | 7,471,794 | | | | | | 8.1% | | |
The Vanguard Group(5) | | | | | 6,475,504 | | | | | | 7.1% | | |
KPCB Holdings, Inc., as nominee(6) | | | | | 6,473,515 | | | | | | 7.1% | | |
Alger Associates, Inc.(7) | | | | | 4,560,319 | | | | | | 5.0% | | |
Directors and Named Executive Officers | | | | | | | | | | | | | |
Peter Anevski(8) | | | | | 1,992,592 | | | | | | 2.1% | | |
Jennifer Bealer(9) | | | | | 75,788 | | | | | | * | | |
Malissia Clinton(10) | | | | | 16,500 | | | | | | * | | |
Fred E. Cohen, M.D. D. Phil.(11) | | | | | 70,137 | | | | | | * | | |
Kevin Gordon(12) | | | | | 58,416 | | | | | | * | | |
Lisa Greenbaum(13) | | | | | 2,112 | | | | | | * | | |
Roger Holstein(14) | | | | | 16,500 | | | | | | * | | |
Mark Livingston(15) | | | | | 51,875 | | | | | | * | | |
Jeff Park(16) | | | | | 73,446 | | | | | | * | | |
Norman Payson, M.D.(17) | | | | | 759,984 | | | | | | * | | |
David Schlanger(18) | | | | | 3,488,992 | | | | | | 3.7% | | |
Beth Seidenberg, M.D.(19) | | | | | 6,780,721 | | | | | | 7.4% | | |
Cheryl Scott(20) | | | | | 56,417 | | | | | | * | | |
All executive officers and directors as a group (13 persons)(21) | | | | | 13,678,790 | | | | | | 14.0% | | |
Beneficial Owner | Beneficial Ownership(1) | |||||||||||||
Number of Shares | Percent of Total | |||||||||||||
Greater than 5% Stockholders | ||||||||||||||
TPG Biotechnology Partners III, L.P.(2) | 9,815,351 | 10.3 | % | |||||||||||
BlackRock(3) | 9,346,854 | 9.9 | % | |||||||||||
The Vanguard Group(4) | 7,345,124 | 7.8 | % | |||||||||||
KPCB Holdings, Inc., as nominee(5) | 6,473,515 | 6.9 | % | |||||||||||
Macquarie Group Limited(6) | 4,988,789 | 5.3 | % | |||||||||||
Directors and Named Executive Officers | ||||||||||||||
Peter Anevski(7) | 2,040,039 | 2.2 | % | |||||||||||
Fred E. Cohen, M.D. D. Phil.(8) | 121,320 | * | ||||||||||||
Lloyd Dean | — | * | ||||||||||||
Kevin Gordon(9) | 103,684 | * | ||||||||||||
Roger Holstein(10) | 61,768 | * | ||||||||||||
Mark Livingston(11) | 237,584 | * | ||||||||||||
Jeff Park(12) | 127,583 | * | ||||||||||||
Norman Payson, M.D.(13) | 551,320 | * | ||||||||||||
David Schlanger(14) | 2,927,527 | 3.1 | % | |||||||||||
Beth Seidenberg, M.D.(15) | 6,837,711 | 7.2 | % | |||||||||||
Cheryl Scott(16) | 100,835 | * | ||||||||||||
Michael Sturmer(17) | 431,757 | * | ||||||||||||
Allison Swartz | — | * | ||||||||||||
All executive officers and directors as a group (13 persons)(18) | 13,541,128 | 14.3 | % |
44 | ||
45 | ||
46 | ||
47 | ||
By Order of the Board of Directors | |||||||||
Executive Vice President, General Counsel and Secretary | |||||||||
April 14, 2023 |
48 | ||
49 | ||
50 | ||